Spots Global Cancer Trial Database for Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Official Title: Multi-center,Middle East, Phase-II Study, Non-comparative, of the RAF-Kinase Inhibitor Sorafenib in Patients With Advanced Renal Cell Carcinoma to Evaluate The Efficacy and Tolerability of the Drug
Study ID: NCT00848640
Conditions
Interventions
Study Description
Brief Summary: The purpose study is to evaluate the efficacy and safety of Sorafenib as first line treatment for patients - unsuitable for another approved first line therapy - with advanced RCC in the Middle East Region.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Egyptian Foundation For Cancer Research, Cairo, , Egypt
Contact Details
Name: Hussein M. Khaled, MD
Affiliation: Egyptian Foundation For Cancer Research
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
